Primary Objectives:
Phase 2 Simon 2-Stage Study (Arm 1 Monotherapy)
Phase 1b (Arm 2 Combination Therapy)
Phase 2 Exploratory Study (Arm 2 Combination Therapy)
Secondary Objectives:
Phase 1b Study (Arm 2 Combination Therapy)
Participant must have radiographic evidence of disease progression based on RECIST criteria following the most recent line of treatment. Biochemical recurrence (eg, CA-125 in ovarian carcinoma) only is not considered as disease progression.
Newly obtained is defined as a specimen obtained up to 6 weeks prior to initiation of treatment on Day 1 if no intercurrent systemic therapy in the interval.
Tumor Specific Inclusion Criteria
For Ovarian Carcinoma:
Platinum sensitive disease, defined as disease which progress after 6 or more months after the completion of platinum-based therapy and primary platinum refractory disease, defined as progression while on the upfront platinum-based therapy, is not eligible.
For Endometrial Carcinoma
For Urothelial Carcinoma
Tumor Specific Exclusion Criteria
For Endometrial Adenocarcinoma:
For Urothelial Carcinoma: